What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) received 4 analyst ratings: 2 bullish, 1 somewhat bullish, and 1 indifferent. The 12-month price targets for DCPH suggest an average target of $22.25, with a high of $30.00 and a low of $14.00. The average price target has increased by 5.95% over the past month. Analysts rate stocks based on future earnings potential and company risk profile, typically updating their ratings quarterly or after significant company events.
November 20, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deciphera Pharmaceuticals has received mostly positive ratings from analysts, with an average 12-month price target of $22.25, indicating potential upside from current levels. The recent increase in the average price target suggests growing optimism about the company's prospects.
The predominance of bullish and somewhat bullish ratings, combined with the recent increase in the average price target, suggests that analysts are optimistic about DCPH's future performance. This could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100